 |
|
|
| |
All-Oral, Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir for Non-Cirrhotic Patients With Chronic HCV Genotype 1 Infection: UNITY-1 Phase 3 SVR12 Results
|
| |
| |
Reported by Jules Levin
AASLD Nov 7-11 Boston 2014
Poordad F,1 Sievert W,2 Mollison L,3 Brau N,4 Levin J,5 Sepe T,6 Lee S,7 Boyer N,8 Bronowicki J-P,9 Jacobson IM,10 Boparai N,11 Hughes E,11 Swenson ES,12 Yin PD12 on behalf of the UNITY-1 Study Team
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 2Monash Health and Monash University, Melbourne, Australia; 3Fremantle Hospital, Hepatitis Services, Fremantle, Australia; 4James J Peters
Veterans Affairs Medical Center, Bronx, New York, NY; 5Dean Foundation, Madison, WI; 6University Gastroenterology, Providence, RI; 7University of Calgary, Calgary, Canada; 8Service d'Hépatologie, Hôpital Beaujon,
Clichy, France; 9Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France; 10Weill Cornell Medical College, New York, NY; 11Bristol-Myers Squibb, Princeton, NJ; 12Bristol-Myers Squibb, Wallingford, CT
|
| |
|
|
|
|
|
